GOLDCREST

Silvercrest reported Q3 2025 EPS of $0.19 versus an expected $0.28 (−32.1%) and revenue of $31.3 million compared with $32.25 million expected. Expenses rose 15.4%, and assets under management reached a new high of $37.6 billion. The stock was unchanged after hours at $14.34; management expects further AUM growth and a return to previous EBITDA margins. » Más en de.investing.com

GOLDCREST is expected to release its quarterly results for September 30, 2025, on October 31, 2025. One analyst forecasts earnings per share of 19.70 JPY, a decline of 45.69% from 36.27 JPY a year earlier. Two analysts expect average quarterly revenue of 6.17 billion JPY, a decrease of 11.41% from 6.97 billion JPY a year earlier. For the current fiscal year, two analysts on average forecast earnings per share of 155.45 JPY and revenue of 30.45 billion JPY. » Más en finanzen.net

Merit Medical’s Embosphere microspheres have been approved in the EU for use in genicular artery embolization (GAE) to treat knee osteoarthritis. In the GENESIS study, more than 75% of patients treated with Embosphere achieved clinical success with significant pain relief lasting up to 24 months, along with reduced analgesic use and improved quality of life. The expanded indication complements existing Embosphere applications and follows strong quarterly results from Merit Medical that exceeded analysts’ estimates. » Más en de.investing.com